Gilder Gagnon Howe & CO LLC Passage Bio, Inc. Transaction History
Gilder Gagnon Howe & CO LLC
- $8.56 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding PASG
# of Institutions
47Shares Held
37.7MCall Options Held
10.5KPut Options Held
0-
Lynx1 Capital Management LP San Juan, PR9.26MShares$4.17 Million2.05% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.4MShares$3.33 Million0.11% of portfolio
-
Vestal Point Capital, LP New York, NY6.1MShares$2.75 Million0.21% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY2.5MShares$1.12 Million1.92% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.46MShares$1.11 Million0.02% of portfolio
About Passage BIO, Inc.
- Ticker PASG
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,463,200
- Market Cap $24.5M
- Description
- Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...